In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
US life sciences venture capital firm Apple Tree Partners has announced $52 million in Series A funding for its portfolio company Deep Apple Therapeutics. 15 December 2023
Pharmaceutical
New York-based neurology specialist Mind Medicine has announced positive topline results from its Phase IIb clinical trial of MM-120. 14 December 2023
Biotechnology
Former Novartis executive James Bradner has joined Amgen as executive vice president of research and development (R&D), and chief scientific officer. 14 December 2023
Biotechnology
Generics giant Teva Pharmaceutical Industries and fellow Israel-based artificial intelligence (AI) focused biotech Biolojic Design have signed a license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma. 14 December 2023
Biotechnology
USA-headquartered biotech CSL Behring, a subsidiary of Australia’s CSL Limited (ASX: CSL), has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of Health, marking the first treatment to be authorized by this innovative process in France. 14 December 2023
Biotechnology
US biotech companies Biogen and Sage Therapeutics have announced that Zurvuvae (zuranolone) is now available by prescription for the treatment of postpartum depression (PPD) for adults in the USA. 14 December 2023
Biotechnology
Biotech major Amgen has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics License Application (BLA) for tarlatamab. 14 December 2023
Pharmaceutical
Swiss neurology specialist GliaPharm has announced a new investment of $4.2 million for its lead program in Alzheimer’s disease. 14 December 2023
Biosimilars
The US subsidiary of South Korea-based Celltrion Healthcare has announced that Ventegra, a major US Medical Benefits Manager (MBM) who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model, will place an FDA-approved biosimilar to Roche’s Avastin (bevacizumab), Vegzelma (bevacizumab-adcd), on its commercial formulary as a preferred brand. 14 December 2023
Pharmaceutical
The Global Health Innovative Technology (GHIT) Fund has announced an investment of approximately $8.8 million for the development of new drugs for malaria and Chagas disease. 14 December 2023
Biosimilars
By 2032, the biosimilar medicines contribution to health systems access and sustainability will soon match the impact of generic medicines, says Medicines for Europe. 14 December 2023
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday announced the establishment of a new Genetic Metabolic Diseases Advisory Committee (GeMDAC) to help the agency explore the complex issues related to genetic metabolic disease drug development. 14 December 2023
Biotechnology
Vertex Pharmaceuticals’ shares were up 9.2% at $390.42 mid-morning, after it announced positive results from its Phase II dose-ranging study of the non-opioid selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN). 13 December 2023
Biotechnology
New York-based pharma giant Pfizer will finally be able to complete its $43 billion acquisition of Seagen, having addressed all of the concerns of antitrust regulators. 13 December 2023
Biotechnology
Allergy Therapeutics saw its share jump more than 8% to 2.10 pence by early afternoon as it released new data on its allergy candidate. 13 December 2023
Biotechnology
South Korea medicines regulator has issued guidelines to monitor the side effects of the two approved CAR-T therapies – Novartis’ Kymriah (tisagenlecleucel) and Johnson & Johnson subsidiary Janssen’ Carvykti (ciltacabtagene autoleucel). 13 December 2023
Biotechnology
Shares of US clinical-stage biotech C4 Therapeutics closed up a massive 98% on Tuesday and gained a further 12.8% to $2.64 pre-market, after the company announced a potentially lucrative deal with US pharma giant Merck & Co. 13 December 2023
Biotechnology
Johnson & Johnson unit Janssen has presented the first data from the Phase III PERSEUS study at the annual meeting of the American Society of Hematology (ASH). 13 December 2023
Biotechnology
Californian antibody specialist Electra Therapeutics has appointed Kathy Dong as president and chief executive, replacing current CEO Adam Rosenthal. 13 December 2023
Biotechnology
US mRNA medicines company Moderna has announced changes to its operating model to bring focus to its short- and long-term business goals. 13 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze